Morgan Stanley analyst Michael Ulz reiterated an Overweight rating and $84.00 price target on Akero Therapeutics (NASDAQ: AKRO)The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE